rapifleX MALDI PharmaPulse® from Bruker Life Sciences Mass Spectrometry

The rapifleX MALDI PharmaPulse (MPP) accelerates label-free hit finding in drug discovery: rapifleX MPP combines the unambiguousness of mass spectrometry with the required speed to comb through large compound libraries of millions of substances.

The use of mass spectrometry allows the measurement of unmodified substrates in primary screens to avoid false positives or false negatives, making confirmation screens redundant. The system is designed for fully automatic handling of 1536 sample plates to screen more than a million compounds in a week in support of drug discovery.

Image Credit:Bruker Life Sciences Mass Spectrometry

New Standard for Ultra-High-Throughput Screening Label-Free ‘Hit’ Identification

By combining the speed of Bruker’s patented Smartbeam™ 3D laser technology with the direct-detection capability of mass spectrometry, the rapifleX MALDI PharmaPulse (MPP) delivers unprecedented screening capability for High-Throughput Screening biochemical assays. It allows you to screen through large and diverse compound libraries at a pace of over a million compounds a week, epitomizing the perfect balance of automation and miniaturization.

The MPP system allows for the measurement of unmodified substrates in primary biochemical screens, and offers several advantages:

It effectively eliminates confirmatory assays typically required of traditional fluorescence-based screening techniques

Saves costs for developing specific fluorescence probes or antibodies

Doesn’t require expensive solvents or consumables for continuous operation

Allow sample volume down to 25 nl

The MPP system is specifically designed for fully automatic handling 384, 1536, 3072 and 6144 samples per plate, including automated method development and instant export to LIMS.

Image Credit:Bruker Life Sciences Mass Spectrometry

The new rapifleX MALDI time-of – flight mass spectrometer is the key enabler for the MALDI PharmaPulse solution. It represents a new era in MALDI mass spectrometry. All performance characteristics of the rapifleX MALDI TOF and TOF/TOF instrument surpasses anything seen before.

The new MALDI PharmaPulse 2.0 software solution completes the rapifleX MALDI PharmaPulse mass spectrometer with a tailored software solution for the provision of HTS campaigns – for non-experts in mass spectrometry. This major step enables scientists working in drug discovery to use label-free mass spectrometry for large screening campaigns of millions of substances.

For Research Use Only. Not for Use in Clinical Diagnostic Procedures.

Bruker MALDI PharmaPulse label free HTS solutionPlay